Suzhou Homesun Pharmaceutical Co. Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation Eperisone Hydrochloride Tablets (Specification: 50 mg, produced by Suzhou Hongsen Pharmaceutical Co., Ltd.) and the reference preparation Eperisone Hydrochloride Tablets (Miao Na®, Specification: 50 mg; produced by Eisai (China) Pharmaceutical Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting or fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. The secondary purpose of the study is to evaluate the safety of the test preparation Eperisone Hydrochloride Tablets and the reference preparation Eperisone Hydrochloride Tablets (Miao Na®) in healthy adult subjects.

Primary objective: To study the pharmacokinetics of the test preparation bisoprolol amlodipine tablets (specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine), produced by Suzhou Hongsen Pharmaceutical Co., Ltd.) and the reference preparation bisoprolol amlodipine tablets (specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine), produced by Egis Pharmaceuticals PLC) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation (T) bisoprolol amlodipine tablets and the reference preparation (R) bisoprolol amlodipine tablets (Kangxinan®) in healthy subjects after a single oral administration in the fasting and fed state.

Primary objective: This study aims to study the pharmacokinetic characteristics of loxoprofen sodium patch (100 mg/patch (10 cm×14 cm)) provided by Suzhou Hongsen Pharmaceutical Co., Ltd. in healthy study participants after single fasting use; loxoprofen sodium patch (Lesong®, 100 mg/patch (10 cm×14 cm)) certified by LEAD CHEMICAL CO., LTD. was used as the reference preparation to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations and evaluate the bioequivalence of the two preparations in humans. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in healthy study participants; 2) To evaluate the adhesion and skin irritation of the test preparation and the reference preparation during the medication process of healthy study participants.